Figma Shares Indicated To Open $105/$110
NORWOOD, Mass. - Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage biotech company with a market capitalization of $117 million and currently trading below its InvestingPro Fair Value, announced Wednesday that updated clinical data from its Phase 1/2 study of CRB-701 will be presented at the European Society for Medical Oncology Congress in October.
The presentation, scheduled for October 19 in Berlin, will showcase results from the ongoing trial evaluating CRB-701, a Nectin-4-targeting antibody-drug conjugate, in patients with urothelial and non-urothelial solid tumors.
The three-part study is assessing safety, pharmacokinetics, and efficacy of CRB-701 in patients with advanced solid tumors that express high levels of Nectin-4. According to the press release, the trial has completed Part A dose escalation, which evaluated four predetermined doses ranging from 1.8 mg/kg to 4.5 mg/kg.
The company is currently conducting dose optimization with 2.7 mg/kg and 3.6 mg/kg cohorts in head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial carcinoma. Corbus expects to complete this phase and identify a recommended Phase 2 dose in the fourth quarter of 2025.
CRB-701, also known as SYS6002, is described as a next-generation antibody-drug conjugate that targets Nectin-4, a clinically validated tumor-associated antigen in urothelial cancer. The drug uses a site-specific cleavable linker with a homogenous drug antibody ratio of 2, utilizing MMAE as its payload.
Corbus Pharmaceuticals focuses on developing treatments for oncology and obesity, with additional pipeline candidates including CRB-601 and CRB-913.
In other recent news, Corbus Pharmaceuticals has made significant strides in its clinical trials and corporate governance. The company announced the initiation of the multiple ascending dose portion of its Phase 1 trial for CRB-913, a drug being developed for obesity treatment. This follows the completion of the single ascending dose portion, with no treatment-related neuropsychiatric events observed. Additionally, an abstract on Corbus’s CRB-701 clinical study has been accepted for presentation at the European Society for Medical Oncology Congress in 2025, highlighting its ongoing research efforts in cancer treatment.
In terms of analyst activity, H.C. Wainwright maintained a Buy rating and a $40 price target for Corbus Pharmaceuticals, while Mizuho Securities adjusted its price target to $32 from $42 but kept an Outperform rating. The company recently held its annual meeting of stockholders, where shareholders reappointed several directors and ratified the company’s independent auditor. These developments reflect Corbus Pharmaceuticals’ continued focus on advancing its clinical pipeline and strengthening its corporate structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.